Hundreds of NHS patients with an incurable form of cervical cancer will be able to get treatment using a combination regimen based on Merck & Co/MSD’s cancer immunothe
NICE has recommended that PTC Therapeutics’ gene therapy for ultra-rare disease aromatic L-amino acid decarboxylase (AADC) deficiency Upstaza be made available for NHS use
Lundbeck’s Vyepti (eptinezumab) has received NICE recommendation for the prevention of migraine in adults experiencing four or more migraine days monthly who have been tre
NICE has recommended eight digital therapies (DTx) for mental health disorders, continuing a drive by the health technology assessment (HTA) agency to review treatment opt
Bristol-Myers Squibb’s Opdivo has become the first immunotherapy to be cleared for NHS use alongside chemotherapy as a pre-surgery (neoadjuvant) therapy for resectable non
UK cost-effectiveness agency NICE has published guidance on the use of COVID-19 therapies that can be used for at-risk patients, focusing on three drugs that can be used o
Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t